Ticagrelor Market Size to Reach USD 3.60 Billion by 2035, Fueled by Rising Cardiovascular Disease Burden and Growing Adoption of Advanced Antiplatelet Therapies – SNS Insider
Increasing Prevalence of Acute Coronary Syndrome, Expanding Post-PCI Treatment Protocols, and Growing Healthcare Infrastructure in Emerging Economies Drive Market Growth.
Austin, March 16, 2026 (GLOBE NEWSWIRE) — Ticagrelor Market Size & Growth Analysis:
“According to SNS Insider, The Ticagrelor Market was valued at USD 1.80 Billion in 2025 and is projected to reach USD 3.60 Billion by 2035, reflecting a compound annual growth rate (CAGR) of 7.18% from 2026 to 2035.”
The increasing global incidence of cardiovascular diseases, including acute coronary syndrome (ACS) and myocardial infarction, continues to be the key factor driving the market for ticagrelor. The clinical efficacy of ticagrelor in the prevention of platelet aggregation and survival has established the drug as a popular antiplatelet drug among cardiologists. The increasing number of percutaneous coronary intervention (PCI) procedures has fueled the market for antiplatelet therapies in the prevention of stent thrombosis.
Get a Sample Report of Ticagrelor Market: https://www.snsinsider.com/sample-request/8207
Lifestyle-related risk factors like obesity, diabetes, hypertension, and physical inactivity have significantly increased the occurrence of coronary artery diseases, thus fueling the market demand over the years. Ticagrelor’s inclusion in various international cardiology guidelines, coupled with the expansion of healthcare facilities in emerging countries and the advent of telecardiology services that ensure timely diagnosis and adherence to treatment, have been instrumental in sustaining the growth trajectory.
The U.S. Ticagrelor Market was valued at USD 0.72 Billion in 2025 and is expected to reach USD 1.45 Billion by 2035, at a CAGR of 7.24%. The U.S. leads the global market driven by its high cardiovascular disease prevalence, advanced treatment infrastructure, robust reimbursement frameworks, and widespread clinical guideline adoption recommending ticagrelor for ACS management across hospitals and specialty cardiac centers.
Major Players Listed in this Report:
- AstraZeneca
- Dr. Reddy’s Laboratories
- Sun Pharmaceutical Industries
- Cipla
- Teva Pharmaceutical Industries
- Lupin Limited
- Cadila Pharmaceuticals
- Aurobindo Pharma
- Zydus Lifesciences
- Hetero Drugs
- Alkem Laboratories
- Apotex Inc.
- Mylan N.V.
- Sandoz International
- Glenmark Pharmaceuticals
- Biocon Limited
- Amneal Pharmaceuticals
- Intas Pharmaceuticals
- Abbott Laboratories
- Pfizer Inc.
Segmentation Analysis
By Dosage Strength
The 90 mg tablets segment accounted for the highest market share of 54.21% in 2025. This can be attributed to the widespread use of ticagrelor in the initial treatment phase for ACS patients. In ACS, rapid platelet inhibition is critical. Additionally, the 60 mg tablets segment is anticipated to grow at the highest CAGR of 7.64%. This can be attributed to the increasing use of this dosage in the long-term secondary prevention of post-MI patients.
By Indication
Acute coronary syndrome accounted for the highest market share of 46.37% in 2025. This can be attributed to the use of ticagrelor as first-line emergency antiplatelet therapy in the treatment of unstable angina and myocardial infarction. Myocardial infarction prevention is anticipated to grow at the highest CAGR of 7.82%. This can be attributed to the increasing importance of long-term secondary prevention protocols and post-MI patient management.
By Distribution Channel
Hospital pharmacies accounted for the highest market share of approximately 51.18% in 2025. This can be attributed to the high number of inpatient cardiovascular treatments. Retail pharmacies and online pharmacies are also gaining popularity in the ticagrelor market. This can be attributed to the transition to long-term secondary prevention therapy. E-pharmacies have also improved the accessibility of medication for chronic cardiovascular patients.
By End User
Hospitals accounted for the highest market share of 55.63% in 2025. This can be attributed to the high number of acute cardiac emergencies, high-end cardiology facilities, and ICU facilities. Additionally, specialty clinics are anticipated to grow at the highest CAGR of 7.91%.
Need Any Customization Research on Ticagrelor Market, Enquire Now: https://www.snsinsider.com/enquiry/8207
Ticagrelor Market Segmentation
By Dosage Strength
- 60 mg Tablets
- 90 mg Tablets
- Others (Any special strengths, combination formulations, or investigational doses)
By Indication
- Acute Coronary Syndrome (ACS)
- Myocardial Infarction (MI) Prevention
- Percutaneous Coronary Intervention (PCI)
- Others (Stroke prevention in high-risk cardiovascular patients, peripheral arterial disease)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others (Specialty cardiac clinics, government tenders, and institutional supply)
By End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others (Research organizations, rehabilitation centers)
Regional Insights
North America has been the market leader in the ticagrelor market, generating around 42.18% of the global ticagrelor market revenue in 2025. This can be attributed to the presence of a robust healthcare infrastructure, a solid pharmaceutical research environment, and a positive reimbursement scenario. Furthermore, the adoption of evidence-based cardiology treatment protocols in the region has been consistently higher. The U.S. has been the largest market for ticagrelor, and the demand for ticagrelor in the region is likely to continue at a similar rate in the coming years.
The Asia-Pacific region is likely to exhibit the fastest regional market growth, with a CAGR of 8.02% during the forecast period. Urbanization and the prevalence of cardiovascular diseases in China and India due to lifestyle factors are likely to drive the market. Government initiatives to improve the accessibility of cardiology care in the region have increased, and investments in hospital infrastructure have accelerated the adoption of advanced antiplatelet agents.
Recent Developments
- In 2024, AstraZeneca advanced collaborative programs with healthcare systems across Asia-Pacific to improve ticagrelor accessibility and treatment adherence among ACS patients in high-growth emerging markets.
- In 2023, several generic pharmaceutical manufacturers, including Sun Pharma and Dr. Reddy’s Laboratories, expanded their ticagrelor generics portfolios to address growing demand in cost-sensitive markets across Asia and Latin America.
Ticagrelor Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 1.80 Billion |
| Market Size by 2035 | USD 3.60 Billion |
| CAGR | CAGR of 7.18% From 2026 to 2035 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Historical Data | 2022-2024 |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Purchase Single User PDF of Ticagrelor Market Report (20% Discount): https://www.snsinsider.com/checkout/8207
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Market Overview
4. Statistical Insights & Trends Reporting
5. Ticagrelor Market Segmental Analysis & Forecast, By Dosage Strength
6. Ticagrelor Market Segmental Analysis & Forecast, By Indication
7. Ticagrelor Market Segmental Analysis & Forecast, By Distribution Channel
8. Ticagrelor Market Segmental Analysis & Forecast, By End-User
9. Ticagrelor Market Segmental Analysis & Forecast, By Region
10. Competitive Landscape
11. Analyst Recommendations
12. Assumptions
13. Disclaimer
14. Appendix
Access Complete Report Details of Ticagrelor Market Analysis & Outlook: https://www.snsinsider.com/reports/ticagrelor-market-8207
[For more information or need any customization research mail us at info@snsinsider.com]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.
